Seven participants across two cohorts dosed in the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9; Initial data planned for the first half of 2025 Dr. Kathiresan continued, “In addition, ...

Announced First Human Proof-of-Concept Data for In Vivo Base Editing from Ongoing Heart-1 Phase 1b Clinical Trial of VERVE-101 in November 2023 Interim Data from Ongoing Heart-1 Phase 1b Clinical ...

Verve Therapeutics' stock remains a "Buy" despite recent setbacks, including the retirement of its Chief Medical Officer and the termination of a collaboration with Vertex. Verve's gene-editing ...

The first treatment candidate from Verve Therapeutics to begin clinical trials recently produced positive results. Shares of the biotech collapsed despite results that show VERVE-101 can control ...

Heart-1 clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg of VERVE-101 Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT elevation ...

Verve Therapeutics Inc (NASDAQ:VERV) on Monday released initial data from the Heart-2 Phase 1b trial of VERVE-102 in patients with heterozygous familial hypercholesterolemia (HeFH) and/or premature ...

Shares of Verve Therapeutics (NASDAQ: VERV) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday. And for good reason. Eli Lilly (NYSE: LLY) and Verve Therapeutics announced a "definitive ...

Verve Therapeutics Inc. shares VERV fell 40% premarket on Monday after the biotech company on Sunday released early-stage clinical trial data on its experimental gene-editing treatment for high ...

It reported some very bad news, but the market might be overreacting. So is this biotech worth buying, or did the market act appropriately and dump Verve's stock because there's something obviously ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verve Therapeutics, a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a person’s risk of ...